A detailed history of Bank Of America Corp transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Bank Of America Corp holds 390,660 shares of SMMT stock, worth $6.98 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
390,660
Previous 341,147 14.51%
Holding current value
$6.98 Million
Previous $2.66 Million 221.62%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.89 - $31.93 $341,144 - $1.58 Million
49,513 Added 14.51%
390,660 $8.56 Million
Q2 2024

Aug 14, 2024

SELL
$2.39 - $10.92 $117,578 - $537,220
-49,196 Reduced 12.6%
341,147 $2.66 Million
Q1 2024

May 15, 2024

BUY
$2.55 - $5.07 $683,530 - $1.36 Million
268,051 Added 219.19%
390,343 $1.62 Million
Q4 2023

Feb 14, 2024

BUY
$1.67 - $2.83 $188,235 - $318,986
112,716 Added 1177.07%
122,292 $319,000
Q2 2023

Aug 14, 2023

SELL
$1.32 - $2.81 $8,910 - $18,967
-6,750 Reduced 41.35%
9,576 $24,000
Q1 2023

May 12, 2023

BUY
$1.38 - $5.41 $10,176 - $39,893
7,374 Added 82.37%
16,326 $28,000
Q4 2022

Feb 10, 2023

BUY
$0.68 - $5.31 $4,942 - $38,593
7,268 Added 431.59%
8,952 $38,000
Q3 2022

Nov 14, 2022

BUY
$0.89 - $1.63 $1,315 - $2,409
1,478 Added 717.48%
1,684 $2,000
Q2 2022

Aug 12, 2022

SELL
$0.92 - $2.38 $8,820 - $22,819
-9,588 Reduced 97.9%
206 $0
Q1 2022

May 16, 2022

SELL
$2.0 - $3.45 $19,034 - $32,833
-9,517 Reduced 49.28%
9,794 $24,000
Q4 2021

Feb 08, 2022

BUY
$2.45 - $5.64 $19,154 - $44,093
7,818 Added 68.02%
19,311 $52,000
Q3 2021

Nov 15, 2021

BUY
$4.83 - $8.27 $13,538 - $23,180
2,803 Added 32.26%
11,493 $57,000
Q2 2021

Sep 13, 2021

BUY
$5.15 - $8.46 $44,753 - $73,517
8,690 New
8,690 $65,000

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $3.6B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.